Beijing Minhai Biotechnology Co., (BioMinhai), a wholly-owned subsidiary of China-based Shenzhen Kangtai Biological Products Co., and Biotis Pharmaceuticals Indonesia recently held a signing ceremony in Beijing, concluding the license and technology transfer agreement for the dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine. 

According to the agreement, BioMinhai will supply the dual-carrier 13-valent pneumococcal vaccine bulk to Biotis, and transfer such technologies as vaccine formulation, filling and finished product testing methods to Biotis. Both parties will also jointly promote the registration, production, and commercial operation of dual-carrier 13-valent pneumococcal conjugate vaccine in Indonesia.

At present, Indonesia has included 11 vaccines in the Expanded Immunisation Programme, and attached increasing importance to pneumococcal conjugate vaccine.

"The 13-valent pneumococcal conjugate vaccine has been included in the National Immunization Program of Indonesia and provided to the general public free of charge, playing a significant role in reducing the incidence of related diseases among children. The international cooperation between Biotis and BioMinhai can help us better meet the challenges in vaccine supply and distribution", said Fransiskus Xaverius Sudirman, President Director of PT Biotis Pharmaceuticals Indonesia.